The combined effect between tucatinib and T-DM1 ultimately lead to synergistic cytotoxicity in HER2-positive breast cancer cell lines and increased antitumor activity in xenograft models, especially those with reduced sensitivity to T-DM1, compared with tucatinib or T-DM1 alone. Here, ERBB2 is linked to breast cancer.